Ciclosporin A kezeléssel szerzett tapasztalataink szisztémás lupus erythematosusban

Translated title of the contribution: Clinical experiences with cyclosporin A in patients with systemic lupus erythematosus

Research output: Contribution to journalArticle

Abstract

Introduction: Cyclosporin A is a peptide composed of 11 aminoacides. Its immune suppressive effect is attributed to the suppression of proliferation of T lymphocytes. Recently, besides immune suppression after organ transplantation it is used in the treatment of autoimmune disorders, such as systemic lupus erythematosus. Aims: In the present work authors examined the frequency, effectiveness and safety of cyclosporin A in patients with systemic lupus erythematosus, regularly followed at the above mentioned department. Results: Of the 450 lupus patients one male and 21 females received cyclosporin A for 12.4 months (3-96). Before cyclosporin A administration 16 patients received combined immune suppressive therapy; 68.2% azathioprin, 27.3% chloroquine, 18.2% methotrexate, while 3 patients were treated with steroid alone. High autoantibody titres clinical activity and the need for reduction of steroid dose were the mean indications. Furthermore, cyclosporin A was started because of leukopenia in 45.5%, polyarthritis in 36.4% or both in 27.3% of patients. Four patients started cyclosporin A to control skin eruptions. Thrombocytopenia, autoimmune hemolysis, Evans' syndrome and pancytopenia indicated this therapy in one patient for each. Clinical effectiveness was indicated by the reduction of mean daily methylprednisolon dose from 25.1 mg to 8.36 mg and also by the reduction of the disease activity index (SLE-DAI) from 9.47 to 2.47 within the first half year of the treatment. Therapy was well-tolerated. Only 3 patients observed hypertrichosis. Cyclosporin A was stopped in 3 cases due to infection and in 1 patient due to bad compliance. Conclusion: Present results suggest that cyclosporin A is an effective and safe treatment also in a certain group of lupus patients, especially with joint, skin and hematologic complications. Further long-term follow-up is required to evaluate late side-effects.

Original languageHungarian
Pages (from-to)2485-2489
Number of pages5
JournalOrvosi Hetilap
Volume146
Issue number49
Publication statusPublished - 2005

Fingerprint

Systemic Lupus Erythematosus
Cyclosporine
Therapeutics
Steroids
Hypertrichosis
Skin
Pancytopenia
Idiopathic Thrombocytopenic Purpura
Methylprednisolone
Leukopenia
Chloroquine
Organ Transplantation
Hemolysis
Methotrexate
Autoantibodies
Compliance
Arthritis
Joints
T-Lymphocytes
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ciclosporin A kezeléssel szerzett tapasztalataink szisztémás lupus erythematosusban. / Tarr, T.; Zeher, M.; Szegedi, G.; Kiss, E.

In: Orvosi Hetilap, Vol. 146, No. 49, 2005, p. 2485-2489.

Research output: Contribution to journalArticle

@article{667088ac11ea436582ba064466465eee,
title = "Ciclosporin A kezel{\'e}ssel szerzett tapasztalataink sziszt{\'e}m{\'a}s lupus erythematosusban",
abstract = "Introduction: Cyclosporin A is a peptide composed of 11 aminoacides. Its immune suppressive effect is attributed to the suppression of proliferation of T lymphocytes. Recently, besides immune suppression after organ transplantation it is used in the treatment of autoimmune disorders, such as systemic lupus erythematosus. Aims: In the present work authors examined the frequency, effectiveness and safety of cyclosporin A in patients with systemic lupus erythematosus, regularly followed at the above mentioned department. Results: Of the 450 lupus patients one male and 21 females received cyclosporin A for 12.4 months (3-96). Before cyclosporin A administration 16 patients received combined immune suppressive therapy; 68.2{\%} azathioprin, 27.3{\%} chloroquine, 18.2{\%} methotrexate, while 3 patients were treated with steroid alone. High autoantibody titres clinical activity and the need for reduction of steroid dose were the mean indications. Furthermore, cyclosporin A was started because of leukopenia in 45.5{\%}, polyarthritis in 36.4{\%} or both in 27.3{\%} of patients. Four patients started cyclosporin A to control skin eruptions. Thrombocytopenia, autoimmune hemolysis, Evans' syndrome and pancytopenia indicated this therapy in one patient for each. Clinical effectiveness was indicated by the reduction of mean daily methylprednisolon dose from 25.1 mg to 8.36 mg and also by the reduction of the disease activity index (SLE-DAI) from 9.47 to 2.47 within the first half year of the treatment. Therapy was well-tolerated. Only 3 patients observed hypertrichosis. Cyclosporin A was stopped in 3 cases due to infection and in 1 patient due to bad compliance. Conclusion: Present results suggest that cyclosporin A is an effective and safe treatment also in a certain group of lupus patients, especially with joint, skin and hematologic complications. Further long-term follow-up is required to evaluate late side-effects.",
keywords = "Cyclosporin A, Effectiveness, Safety, SLE",
author = "T. Tarr and M. Zeher and G. Szegedi and E. Kiss",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "2485--2489",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "49",

}

TY - JOUR

T1 - Ciclosporin A kezeléssel szerzett tapasztalataink szisztémás lupus erythematosusban

AU - Tarr, T.

AU - Zeher, M.

AU - Szegedi, G.

AU - Kiss, E.

PY - 2005

Y1 - 2005

N2 - Introduction: Cyclosporin A is a peptide composed of 11 aminoacides. Its immune suppressive effect is attributed to the suppression of proliferation of T lymphocytes. Recently, besides immune suppression after organ transplantation it is used in the treatment of autoimmune disorders, such as systemic lupus erythematosus. Aims: In the present work authors examined the frequency, effectiveness and safety of cyclosporin A in patients with systemic lupus erythematosus, regularly followed at the above mentioned department. Results: Of the 450 lupus patients one male and 21 females received cyclosporin A for 12.4 months (3-96). Before cyclosporin A administration 16 patients received combined immune suppressive therapy; 68.2% azathioprin, 27.3% chloroquine, 18.2% methotrexate, while 3 patients were treated with steroid alone. High autoantibody titres clinical activity and the need for reduction of steroid dose were the mean indications. Furthermore, cyclosporin A was started because of leukopenia in 45.5%, polyarthritis in 36.4% or both in 27.3% of patients. Four patients started cyclosporin A to control skin eruptions. Thrombocytopenia, autoimmune hemolysis, Evans' syndrome and pancytopenia indicated this therapy in one patient for each. Clinical effectiveness was indicated by the reduction of mean daily methylprednisolon dose from 25.1 mg to 8.36 mg and also by the reduction of the disease activity index (SLE-DAI) from 9.47 to 2.47 within the first half year of the treatment. Therapy was well-tolerated. Only 3 patients observed hypertrichosis. Cyclosporin A was stopped in 3 cases due to infection and in 1 patient due to bad compliance. Conclusion: Present results suggest that cyclosporin A is an effective and safe treatment also in a certain group of lupus patients, especially with joint, skin and hematologic complications. Further long-term follow-up is required to evaluate late side-effects.

AB - Introduction: Cyclosporin A is a peptide composed of 11 aminoacides. Its immune suppressive effect is attributed to the suppression of proliferation of T lymphocytes. Recently, besides immune suppression after organ transplantation it is used in the treatment of autoimmune disorders, such as systemic lupus erythematosus. Aims: In the present work authors examined the frequency, effectiveness and safety of cyclosporin A in patients with systemic lupus erythematosus, regularly followed at the above mentioned department. Results: Of the 450 lupus patients one male and 21 females received cyclosporin A for 12.4 months (3-96). Before cyclosporin A administration 16 patients received combined immune suppressive therapy; 68.2% azathioprin, 27.3% chloroquine, 18.2% methotrexate, while 3 patients were treated with steroid alone. High autoantibody titres clinical activity and the need for reduction of steroid dose were the mean indications. Furthermore, cyclosporin A was started because of leukopenia in 45.5%, polyarthritis in 36.4% or both in 27.3% of patients. Four patients started cyclosporin A to control skin eruptions. Thrombocytopenia, autoimmune hemolysis, Evans' syndrome and pancytopenia indicated this therapy in one patient for each. Clinical effectiveness was indicated by the reduction of mean daily methylprednisolon dose from 25.1 mg to 8.36 mg and also by the reduction of the disease activity index (SLE-DAI) from 9.47 to 2.47 within the first half year of the treatment. Therapy was well-tolerated. Only 3 patients observed hypertrichosis. Cyclosporin A was stopped in 3 cases due to infection and in 1 patient due to bad compliance. Conclusion: Present results suggest that cyclosporin A is an effective and safe treatment also in a certain group of lupus patients, especially with joint, skin and hematologic complications. Further long-term follow-up is required to evaluate late side-effects.

KW - Cyclosporin A

KW - Effectiveness

KW - Safety

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=33644854494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644854494&partnerID=8YFLogxK

M3 - Article

C2 - 16398313

AN - SCOPUS:33644854494

VL - 146

SP - 2485

EP - 2489

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 49

ER -